Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (EPPIK)

A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.

Study Overview

• Status: Recruiting
• Conditions: Focal Segmental Glomerulosclerosis; Immunoglobulin A Nephropathy; Minimal Change Disease; Alport Syndrome; IgA Vasculitis
• Intervention / Treatment: Drug: Sparsentan; Drug: Sparsentan; Drug: Sparsentan

Detailed Description

This is a multicenter, open-label, 112-week study of sparsentan in approximately 67 pediatric subjects aged ≥1 year to <18 years with selected proteinuric glomerular diseases, divided into 3 populations, defined as follows:

• Population 1: Subjects with selected proteinuric glomerular diseases associated with Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD) histological patterns
• Population 2: Subjects with kidney biopsy-confirmed immunoglobulin A nephropathy (IgAN), immunoglobulin A vasculitis (IgAV), or Alport syndrome (AS)
• Population 3: Subjects with kidney biopsy-confirmed IgAN

The study will evaluate long-term safety, tolerability, and efficacy with pharmacokinetic (PK) evaluations at Day 1 (Baseline), Day 2 (Visit 4), and Week 12 (Visit 9) in Population 1 and Population 2. In Population 3, PK values will be evaluated at Day 1 (Baseline) and at Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96. For Population 1 and Population 2, subjects will be enrolled in 3 cohorts based on age ranges. For Population 3, subjects will be enrolled in one cohort.

Study Enrollment:

• Population 1: FSGS and/or MCD (30 subjects total)

  1. Cohort 1 (6 subjects): ≥8 years to <18 years
  2. Cohort 2 (18 subjects): ≥3 years to <8 years
  3. Cohort 3 (6 subjects): ≥1 year to <3 years

• Population 2: IgAN, IgAV, or AS (27 subjects total)

  1. Cohort 1 (9 subjects): ≥8 years to <18 years
  2. Cohort 2 (12 subjects): ≥5 years to <8 years
  3. Cohort 3 (6 subjects): ≥2 years to <5 years
• Population 3: IgAN (10 subjects total) 1. 10 subjects: ≥8 years to <18 years

• Study Type: Interventional
• Enrollment (Estimated): 67
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Travere Call Center; Phone Number: 1-877-659-5518; Email: medinfo@travere.com

Study Locations

• Germany
  • Cologne, Germany, 50937
    • Recruiting
    • Uniklinik Köln, Klinik und Poliklinik für Kinder- und Jugendmedizin
  • Hamburg, Germany, 20246
    • Recruiting
    • Universitätsklinikum Hamburg-Eppendorf
  • Heidelberg, Germany, 69120
    • Recruiting
    • Universitätsklinikum Heidelberg - Angelika Lautenschläger - Kinderklinik
• Italy
  • Bari, Italy, 70126
    • Recruiting
    • Policlinico Bari Ospedale Pediatrico Giovanni XXIII
  • Genova, Italy, 16147
    • Recruiting
    • IRCCS Istituto Giannina Gaslini
  • Milan, Italy, 20122
    • Recruiting
    • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
  • Padova, Italy, 35128
    • Recruiting
    • Azienda Ospedale Universita Di Padova
  • Roma, Italy, 00165
    • Recruiting
    • Ospedale Pediatrico Bambino Gesu
• Netherlands
  • Amsterdam, Netherlands, 1105 AZ
    • Recruiting
    • Emma Kinderziekenhuis
  • Nijmegen, Netherlands, 6525 GA
    • Withdrawn
    • Radboud Universitair Medisch Centrum
• Poland
  • Krakow, Poland, 30-663
    • Recruiting
    • Uniwersytecki Szpital Dzieciecy w Krakowie
  • Lodz, Poland, 93-338
    • Withdrawn
    • Instytut Centrum Zdrowia Matki Polki
  • Warsaw, Poland, 04-730
    • Withdrawn
    • Instytut Pomnik - Centrum Zdrowia Dziecka
• Spain
  • Barcelona, Spain, 08035
    • Recruiting
    • Hospital Universitari Vall d'Hebrón
  • Madrid, Spain, 28041
    • Recruiting
    • Hospital Universitario 12 de Octubre
  • Madrid, Spain, 28046
    • Recruiting
    • Hospital Universitario La Paz
  • Seville, Spain, 41013
    • Recruiting
    • Hospital Universitario Virgen del Rocío
• Sweden
  • Gothenburg, Sweden, 416 85
    • Recruiting
    • Drottning Silvias barn- och ungdomssjukhus
  • Stockholm, Sweden, 141 86
    • Recruiting
    • Karolinska Universitetssjukhuset Huddinge
• United Kingdom
  • Bristol, United Kingdom, BS2 8BJ
    • Recruiting
    • University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Hospital for Children
  • Glasgow, United Kingdom, G51 4TF
    • Recruiting
    • NHS Greater Glasgow and Clyde, Royal Hospital for Children
  • Liverpool, United Kingdom, L12 2AP
    • Recruiting
    • Alder Hey Children's NHS Foundation Trust
  • London, United Kingdom, WC1N3JH
    • Recruiting
    • Great Ormond Street Hospital for Children NHS foundation trust
  • Manchester, United Kingdom, M13 9WL
    • Recruiting
    • Manchester University NHS Foundation Trust
• United States
  • California
    • Los Angeles, California, United States, 90048
      • Recruiting
      • Cedars-Sinai Medical Center
  • Delaware
    • Wilmington, Delaware, United States, 19803
      • Recruiting
      • Nemours Children's Hospital
  • Florida
    • Miami, Florida, United States, 33155
      • Recruiting
      • Nicklaus Children's Hospital
    • Miami, Florida, United States, 33136
      • Recruiting
      • University of Miami, Leonard M. Miller School of Medicine
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • Withdrawn
      • University of Iowa, Stead Family Children's Hospital
  • Massachusetts
    • Boston, Massachusetts, United States, 02111
      • Withdrawn
      • Floating Hospital for Children at Tufts Medical Center
  • Michigan
    • Ann Arbor, Michigan, United States, 48109-5008
      • Recruiting
      • C.S. Mott Children's Hospital
  • Minnesota
    • Minneapolis, Minnesota, United States, 55454
      • Recruiting
      • University of Minnesota, Masonic Children's Hospital
  • Missouri
    • Kansas City, Missouri, United States, 64108
      • Recruiting
      • Children's Mercy Hospitals and Clinics
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Recruiting
      • Hackensack University Medical Center
    • Neptune City, New Jersey, United States, 07753
      • Recruiting
      • Jersey Shore University Medical Center
  • New York
    • New Hyde Park, New York, United States, 11042
      • Recruiting
      • Cohen Children's Medical Center
    • New York, New York, United States, 10016
      • Withdrawn
      • Fink Children's Ambulatory Care Center
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • Recruiting
      • University of North Carolina at Chapel Hill
    • Charlotte, North Carolina, United States, 28203
      • Completed
      • Atrium Health Levine Children's Hospital
    • Durham, North Carolina, United States, 22710
      • Recruiting
      • Duke Molecular Physiology Institute
  • Ohio
    • Columbus, Ohio, United States, 43205
      • Recruiting
      • Nationwide Children's Hospital
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • Recruiting
      • University of Oklahoma Health Sciences Center (OUHSC)
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Recruiting
      • Children's Hospital of Philadelphia
    • Philadelphia, Pennsylvania, United States, 19134
      • Withdrawn
      • St. Christopher's Hospital for Children
  • Texas
    • Houston, Texas, United States, 77030
      • Recruiting
      • Texas Children's Hospital
    • Houston, Texas, United States, 77030
      • Withdrawn
      • UT Health - John P. and Kathrine G. McGovern Medical School
  • Washington
    • Seattle, Washington, United States, 98105
      • Recruiting
      • Seattle Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 17 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria for All Subjects (All Three Populations):

A subject must meet all of the following criteria to be eligible for participation in this study:

• The subject or parent/legal guardian (as appropriate) is willing and able to provide signed informed consent/assent, and where required, the subject is willing to provide assent before any screening procedures per local requirements.
• The subject has an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 at screening.
• The subject has a mean seated blood pressure between the 5th and 95th percentile for sex and height.

Inclusion Criteria for Population 1:

• The subject is male or female ≥1 year at screening and <18 years of age at Day 1 (Baseline).
• The subject has a UP/C ≥1.5 g/g (170 mg/mmol) at screening AND one of the following:
• Kidney biopsy-proven FSGS or MCD histological patterns and clinical presentation consistent with primary FSGS or MCD and qualifying proteinuria at screening despite history or ongoing treatment with corticosteroids and/or other immunosuppressive disease-modifying agents.
• Documentation of a genetic mutation in a podocyte protein associated with FSGS or MCD. Subjects with a documented podocytic mutation do not require kidney biopsy.
• Kidney biopsy-proven FSGS histological pattern with medical history and clinical presentation consistent with maladaptive cause of the lesion.

Note: The kidney biopsy may have been performed at any time in the past but must include light microscopy and electron microscopy characteristics and/or immunofluorescence findings consistent with FSGS or MCD.

Inclusion Criteria for Population 2:

• The subject is male or female ≥2 years at screening and <18 years of age at Day 1 (Baseline).
• The subject has UP/C ≥0.6 g/g (68 mg/mmol) at screening AND one of the following diagnoses:
• Kidney biopsy-confirmed IgAN, IgAV, or AS
• Diagnosis of AS by genetic testing (pathogenic X-linked Collagen, Type IV, Alpha-5 (COL4A5) mutation OR autosomal-recessive mutations in both alleles of Collagen, Type IV, Alpha-3 (COL4A3) and/or Collagen, Type IV, Alpha-4 (COL4A4) OR autosomal-dominant COL4A3 and/or COL4A4 and digenic mutations [ie, simultaneous mutations in 2 of the COL4A3, COL4A4, and COL4A5 genes])

Inclusion Criteria for Population 3:

• The subject is male or female ≥8 years at screening and <18 years of age at Day 1 (Baseline).
• The subject has UP/C ≥1.0 g/g (113 mg/mmol) at screening AND has kidney biopsy-confirmed IgAN
• Subject weighs ≥40 kg
• The subject has been on ACEI and/or ARB therapy for at least 12 weeks prior to screening

Exclusion Criteria for All Subjects (All Three Populations):

A subject who meets any of the following will be excluded from this study:

• The subject weighs <7.3 kg at screening.
• The subject has FSGS or MCD histological pattern secondary to viral infections, drug toxicities, or malignancies.
• The subject has immunoglobulin A (IgA) glomerular deposits not in the context of primary IgAN or IgAV (ie, secondary to another condition; eg, systemic lupus erythematosus and liver cirrhosis).
• The subject has had an acute onset or presentation of glomerular disease or a diagnostic biopsy or a relapse of glomerular disease requiring new or different class of immunosuppressive treatment (including, but not limited to, systemic corticosteroids, calcineurin inhibitors and mycophenolate mofetil, abatacept, cyclophosphamide, rituximab, ofatumumab, and ocrelizumab) within 6 months before screening.
• Subjects taking chronic immunosuppressive medications (including systemic steroids) not on a stable dose for ≥1 month before screening.
• The subject requires any of the prohibited concomitant medications as defined in the study protocol.
• The subject has undergone any organ transplantation, with the exception of corneal transplants.
• The subject has a documented history of congenital or acquired heart failure (modified Ross heart failure classification for children Class II to Class IV) and/or previous hospitalization for heart failure or unexplained dyspnea, orthopnea, paroxysmal nocturnal dyspnea, ascites, and/or peripheral edema.
• The subject has hemodynamically significant cardiac valvular disease.
• The subject has clinically significant congenital vascular disease.
• The subject has jaundice, hepatitis, or known hepatobiliary disease, or alanine aminotransferase and/or aspartate aminotransferase >2 times the upper limit of the normal range at screening.
• The subject has a history of malignancy within the past 2 years.
• The subject has a screening hematocrit <27% (0.27 L/L) or a hemoglobin value <9 g/dL (90 g/L).
• The subject has a screening potassium value >5.5 milliequivalent (mEq)/L (5.5 mmol/L).
• The subject has any abnormal clinical laboratory screening values that are considered by the Investigator to be clinically significant.
• The subject has a history of allergic response to any angiotensin II antagonist or endothelin receptor antagonist, including sparsentan, or has a hypersensitivity to any of the excipients in the study medication.
• The female subject is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.
• Female subjects of childbearing potential, beginning at menarche, who do not agree to use 1 highly reliable (ie, can achieve a failure rate of <1% per year) method of contraception from 7 days before the first dose of the study medication until 28 days after the last dose of study medication. Examples of highly reliable contraception methods include stable oral, implanted, transdermal, or injected contraceptive hormones associated with the inhibition of ovulation or an intrauterine device. One additional barrier method must also be used during vaginal sexual activity, such as a diaphragm, diaphragm with spermicide (preferred), or male partner's use of male condom or male condom with spermicide (preferred), from Day 1/Randomization until 28 days after the last dose of study medication. Female subjects of childbearing potential are defined as those who are fertile after menarche, unless permanently sterile; permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. All female subjects of childbearing potential must have a negative serum pregnancy test result at screening (Visit 1) and a negative urine pregnancy test result, with positive results confirmed by serum, at every study visit from Day 1 (Visit 3) and after.

Note: Before menarche, pregnancy testing and contraceptive use are not required. However, subjects and their parents/legal guardians must be advised that, immediately upon menarche, subjects will be required to begin pregnancy testing and initiate contraceptive use. This requirement cannot be waived.

• The subject has participated in a study of another study medication within 28 days before screening or plans to participate in such a study during the course of this study.
• The subject has had prior exposure to sparsentan.
• The subject or parent/legal guardian (as appropriate), in the opinion of the Investigator, are unable to adhere to the requirements of the study including but not limited to, a history of noncompliance and/or any other reason that causes the Investigator to believe the subject would not be a good candidate for the study.
• For Population 3 - the subject is unable to swallow the study medication tablets whole.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Population 1: FSGS and/or MCD; Subjects with selected proteinuric glomerular diseases associated with FSGS and MCD histological patterns	Drug: Sparsentan; Population 1: 800 mg Sparsentan (oral suspension); Other Names: RE-021; Drug: Sparsentan; Population 2: 400 mg Sparsentan (oral suspension); Other Names: RE-021; Drug: Sparsentan; Population 3: 400 mg Sparsentan (tablets); Other Names: RE-021
Experimental: Population 2: IgAN, IgAV, or AS; Subjects with kidney biopsy-confirmed immunoglobulin A nephropathy (IgAN), immunoglobulin A vasculitis (IgAV), or Alport syndrome (AS)	Drug: Sparsentan; Population 1: 800 mg Sparsentan (oral suspension); Other Names: RE-021; Drug: Sparsentan; Population 2: 400 mg Sparsentan (oral suspension); Other Names: RE-021; Drug: Sparsentan; Population 3: 400 mg Sparsentan (tablets); Other Names: RE-021
Experimental: Population 3: IgAN; Subjects with kidney biopsy-confirmed IgAN	Drug: Sparsentan; Population 1: 800 mg Sparsentan (oral suspension); Other Names: RE-021; Drug: Sparsentan; Population 2: 400 mg Sparsentan (oral suspension); Other Names: RE-021; Drug: Sparsentan; Population 3: 400 mg Sparsentan (tablets); Other Names: RE-021

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of interest (AEOIs)	The incidence of TEAEs, SAEs, AEs leading to treatment discontinuation, and AEOIs	After the last patient has undergone the week 108 visit (Visit 15).
Urine protein/creatinine ratio (UP/C) at week 108	Change from baseline in UP/C over 108 weeks	After the last patient has undergone the Week 108 visit (Visit 15)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Steady-state PK parameters area under the plasma concentration-time curve during a dosing interval ([AUCτ])	Steady-state PK parameters [AUCτ]	Week 108
Observed plasma Pharmacokinetic (PK) concentrations	Observed plasma PK concentrations at scheduled timepoints and visits	At scheduled Day 1, Day 2 and Week 12 visits for Population 1 and 2. At scheduled Day 1 and Week 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96 visits for Population 3.
Steady-state PK parameters [Cmax_ss]	Maximum steady-state plasma drug concentration [Cmax_ss]	Week 108
Steady-state PK parameters [Cmin_ss]	Minimum steady-state plasma drug concentration [Cmin_ss]	Week 108
Urine albumin/creatinine ratio (UA/C) over 108 weeks	Change from baseline in UA/C over 108 weeks	Week 108
Estimated glomerular filtration rate (eGFR) over 108 weeks	Change from baseline in eGFR over 108 weeks	Week 108
Proportion of subjects achieving complete remission of proteinuria	The proportion of subjects achieving complete remission of proteinuria, defined as UP/C <0.3 g/g over 108 weeks	Week 108
Proportion of subjects with FSGS and/or MCD histological patterns achieving partial remission	The proportion of subjects with FSGS and/or MCD histological patterns achieving partial remission defined as UP/C ≤1.5 g/g and >40% reduction in UP/C over 108 weeks	Week 108
Proportion of subjects who discontinue study medication due to inability to tolerate the oral suspension	The proportion of subjects who discontinue study medication due to inability to tolerate the smell, taste, aftertaste, volume of administration, or method of administration of oral suspension in Population 1 and Population 2	Week 108

Collaborators and Investigators

• Sponsor: Travere Therapeutics, Inc.
• Investigators: Study Director: Radko Komers, MD, PhD, Travere Therapeutics, Inc.

Publications and helpful links

General Publications

• Rheault MN. Treatment Approaches for Alport Syndrome. J Am Soc Nephrol. 2026 Jan 1;37(1):172-179. doi: 10.1681/ASN.0000000897. Epub 2025 Sep 12.

Helpful Links

• Sponsor Website
• Study Website

Study record dates

Study Major Dates

• Study Start (Actual): August 12, 2021
• Primary Completion (Estimated): March 12, 2027
• Study Completion (Estimated): April 12, 2027

Study Registration Dates

• First Submitted: July 29, 2021
• First Submitted That Met QC Criteria: August 4, 2021
• First Posted (Actual): August 13, 2021

Study Record Updates

• Last Update Posted (Actual): May 12, 2026
• Last Update Submitted That Met QC Criteria: May 8, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Alport, AS, FSGS, IgAN, IgAV, MCD, pediatrics, peds
• Additional Relevant MeSH Terms: Urogenital Diseases; Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Skin Manifestations; Hypersensitivity; Hematologic Diseases; Skin Diseases; Congenital Abnormalities; Blood Coagulation Disorders; Skin Diseases, Vascular; Hemostatic Disorders; Hemorrhagic Disorders; Urogenital Abnormalities; Vasculitis; Glomerulonephritis; Nephritis; Purpura; Collagen Diseases; Nephrosis; Immune Complex Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases; Signs and Symptoms; Hemic and Lymphatic Diseases; Glomerulonephritis, IGA; Glomerulosclerosis, Focal Segmental; Nephritis, Hereditary; Nephrosis, Lipoid; IgA Vasculitis; Macular dystrophy, corneal type 1; sparsentan
• Other Study ID Numbers: RTRX-RE021-201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.
• IPD Sharing Time Frame: Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication.
• IPD Sharing Access Criteria: Requires submission and approval of intended use and a data sharing agreement.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No